Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu) Aberrant expression of CCR4 in diffuse large B-cell lymphoma, not otherwise specified Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) is the largest category of aggressive lymphoma; it is regarded as a heterogeneous group of lymphomas in terms of surface marker expression, histology and clinical features. 1 In this study, we assessed the expression profiles of CC chemokine receptor 4 (CCR4) in DLBCL, NOS cells.
We examined 80 previously untreated patients with DLBCL, NOS who were diagnosed and treated between 2002 and 2012. All patients were initially treated with an R-CHOP regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. Diagnosis of DLBCL, NOS was based on the World Health Organization classification system. 1 Patients were classified into the following four groups on the basis of the International Prognostic Index (IPI) classification: low risk (IPI score ¼ 0-1), low-intermediate risk (IPI score ¼ 2), high-intermediate risk (IPI score ¼ 3) and high risk (IPI score ¼ 4-5). 2 Tumor tissues obtained from every patient by lymph node biopsy were fixed in 10% formalin and embedded in paraffin. Four-micrometer-thick sections were cut and stained with hematoxylin and eosin (H&E). Immunohistological staining was performed using the following primary antibodies: CD3 (PS1; Nichirei, Tokyo, Japan), CD5 (4C7; Nichirei), CD10 (56C6; Dako, Glostrup, Denmark), CD20 (SL26; Kyowa Medix, Tokyo, Japan), BCL6 (LN22; Novocastra, Newcastle, UK), MUM1 (MUM1p; Dako), CCR4 (KM2160; Kyowa Hakko Kirin, Inc., Tokyo, Japan) and FoxP3 (236A/E7; Abcam, Cambridge, UK). A case was considered positive when^30% of the tumor cells were positive for CD10, BCL6 and MUM1. 3 For CD5, membranous reactivity in^20% of the tumor cells indicated positivity. 4 For immunophenotypic subdivisions, patients with DLBCL, NOS who were positive for CD10 or BCL6 and negative for MUM1 were regarded to have a germinal center-like (GCB) phenotype and other patients with DLBCL, NOS were considered to have a nongerminal center-like (non-GCB) phenotype according to the method of Hans et al. 3 Histological sections were independently examined by two pathologists.
Associations between CCR4 expression and clinical or pathological variables were determined using Fisher's exact test. Overall survival (OS) was calculated as the time between the onset of treatment and death or the date of the last follow-up evaluation. Progression-free survival (PFS) was calculated from the onset of treatment until relapse, disease progression or the last follow-up evaluation. OS and PFS were estimated using the Kaplan-Meier method, and statistical comparisons were made using the log-rank test. Univariate analyses were performed using the Cox proportional hazards regression model and the likelihood ratio test. A P-value o5% was considered statistically significant. Statistical analyses were performed using JMP version Pro.10 software (SAS Institute, Inc., Cary, NC, USA).
The clinicopathological features of the patients at presentation are summarized in Tables 1a and b. Histological examination of the H&E-stained lymph node biopsy specimens revealed diffuse proliferation of large lymphoid cells and complete effacement of the normal architecture of the lymph node (Figure 1a) . The large lymphoid cells were positive for CD20 and negative for CD3. Among the 80 patients, 23 (29%) and 57 patients (71%) had GCB and non-GCB phenotypes, respectively. Regarding CCR4 protein immunostaining using anti-CCR4 antibody, 10 patients (12.5%) were positive and 70 patients (87.5%) were negative. Representative photomicrographs for these staining patterns are shown in completely negative for FoxP3, and a representative photomicrograph for this staining pattern is shown in Figure 1d .
The Kaplan-Meier survival curves for OS and PFS rates with respect to the CCR4 expression status are shown in Figures 1e and f, respectively. There was no significant difference between CCR4-positive and CCR4-negative patients in terms of both OS (P ¼ 0.3236, log-rank test) and PFS (P ¼ 0.6334, log-rank test). As shown in Tables 1c and d , univariate Cox proportional hazard regression analysis was used to assess the following prognostic factors for OS (Table 1c) and PFS (Table 1d ): CCR4 expression, age, sex, clinical stage, IPI category and immunophenotypic subdivision. The results demonstrated that clinical stage and IPI category were significant prognostic factors for OS and PFS, whereas age, sex, immunophenotypic subdivision, and CCR4 expression were not prognostic factors. P-values for CCR4 expression were not significant for OS (P ¼ 0.2860) and PFS (P ¼ 0.6267); thus, CCR4 expression had no prognostic impact on OS and PFS.
Previous studies on immune mechanisms have mainly focused on the effector functions of immune responses during immunopathogenesis. Since the discovery of forkhead box P3 (Foxp3) T regulatory cells (Treg cells), which suppress antigen (Ag)-specific immune effector cells, negative immune regulation has been noted to characterize the pathogenesis of autoimmunological and allergic inflammatory diseases. Foxp3 is the key transcription factor that is likely to have a key role in controlling the expression of critical suppression-mediating molecules. Recently, the presence of Foxp3 þ B regulatory cells (Breg cells) was recently reported, 5 and these cells appear to have a function similar to that of Foxp3 þ Treg cells and negatively regulate allergic diseases. 6 CCR4 is known to be selectivity expressed on Th2 and Treg cells in normal T cells but not in normal B cells. CCR4 is known to be expressed in certain subtypes of T-cell lymphomas. 7 Immunohistochemically, tumor cells from patients with adult T-cell lymphoma/leukemia (ATLL) expressed CCR4 at a high rate of 88.3%. 8 In ALK-negative anaplastic large-cell lymphoma (ALCL), mycosis fungoides in transformation, peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma, CCR4 was positive in 66.7%, 41.2%, 38% and 38% of tumor cells, respectively. 7 In ALK-positive ALCL, extranodal NK/T-cell lymphoma and precursor T-lymphoblastic lymphoma, CCR4 was rarely expressed; they were positive for CCR4 at 4.2%, 3.7% and 0%, respectively. Representative results with a significant P-value are shown among all combinations.
Letters to the Editor suggesting a possible association of CCR4-positive tumors with Treg cells and thereby with an immunocompromised state. 7, 9 Thus, it can be envisaged that FoxP3-positive lymphoma cells would form an immunosuppressive environment around these lymphoma cells themselves, allowing them to escape from host immunosurveillance. In fact, ATLL, in which CCR4 and FoxP3 are immunohistochemically expressed at high rates, 10 has a very poor prognosis, and patients with ATLL are in a severely immunocompromised state. A recent report demonstrated that patients with CCR4-positive ATLL had a worse outcome than those with CCR4-negative ATLL, indicating that CCR4 has an important pathogenic role in ATLL. 8 In contrast, there are only two case reports of CCR4-positive DLBCL, NOS. However, Foxp3 expression has not been described in these reports. 11, 12 Furthermore, there are no reports regarding the aberrant expression frequency of CCR4 in DLBCL, NOS cells themselves and the relationship between aberrant CCR4 expression and patient prognosis. Therefore, we performed an immunohistochemical study of lymph nodes obtained from 80 patients with DLBCL, NOS. This study revealed that aberrant CCR4 expression was found in no less than 12.5% of patients and that interestingly, all CCR4-positive DLBCL, NOS cells were completely negative for FoxP3. There was no significant difference in both OS and PFS between patients with CCR4-positive and CCR4-negative DLBCL, NOS, which may be due to the absence of FoxP3 in CCR4-positive DLBCL, NOS cells, in contrast to patients with ATLL. CCR4-positive and FoxP3-negative DLBCL, NOS may not originate from Breg cells and therefore could not result in tumorinduced immunosuppression, a crucial tumor immune-evasion mechanism.
Mogamulizumab was developed as a new therapeutic antibody targeting CCR4 that enhances antibody-dependent cellular cytotoxic (ADCC) activity. 13 It induces favorable responses in patients with CCR4-positive ATLL and has a less severe toxicity profile, even in the elderly.
14 This study suggested that some cases of CCR4-positive DLBCL with aberrant CCR4 expression are new targets for mogamulizumab treatment. The most common nonhematological adverse effect of mogamulizumab is an infusion reaction. 15 This phenomenon may be associated with the decrease in the number of CCR4-positive and FoxP3-positive lymphoma cells functioning as Treg cells induced by mogamulizumab. Therefore, in cases of CCR4-positive and FoxP3-negative DLBCL, NOS, which does not appear to originate from Breg cells, mogamulizumab may less likely induce an infusion reaction. This therapy is a new strategy for patients with DLBCL, NOS who are currently unsuitable for intensive chemotherapy.
We believe this study sheds further light on the clinicopathological features of CCR4-positive DLBCL, NOS, which may constitute a unique subtype of DLBCL, NOS. For further characterization, additional studies with larger sample sizes and longer follow-up durations are required. Only 30-40% of adult patients with acute lymphoblastic leukemia (ALL) achieve long-term, disease-free survival and can be considered cured. The remainder will eventually relapse and die from disease progression or other ALL-related consequences. 1, 2 Relapse most frequently originates in the bone marrow (BM), 3 where stroma protects ALL cells against drug treatment. , in a process that has been named environmental-mediated drug resistance. Microarray analysis on precursor B-lineage (pre-B) ALL cells from a BCR/ABL transgenic mouse model for Ph-positive ALL undergoing environmentalmediated drug resistance showed significantly increased expression of mRNAs related to stress and inflammation. 6 Among others, we found that transcript levels of the Galectin-3 gene (Lgals3) were significantly increased upon development of resistance to the Bcr/Abl-targeted tyrosine kinase inhibitor nilotinib, and this was also seen in pre-B ALL cells isolated from the BM of BCR/ABL transgenic mice that had been treated with nilotinib for 8 days. 6 Galectin-3, a 30-kDa protein without enzymatic activity, belongs to the family of lectins, which recognize and specifically bind (mostly extracellular) carbohydrate structures. Galectin-3 has a C-terminal carbohydrate-binding domain with preference for galactose and poly-N-acetyllactosamine-modified glycans. Its N-terminal domain promotes homotypic oligomerization. Because of these domains, extracellular Galectin-3 can promote the crosslinking and lattice formation between glycan-containing molecules on the cell surface. 7 ALL cells were reported not to express Galectin-3. 8 The induction of its transcripts in the pre-B ALL cells prompted us to further examine this. We first assessed expression of Galectin-3 protein in BM samples from ALL patients using fluorescenceactivated cell sorting (FACS). Galectin-3 was clearly present in pre-B cells from BM of all four ALL patients (Figure 1a) . Elevated serum levels of Galectin-3 were reported in some types of cancer such as metastatic colorectal cancer and melanoma. 9, 10 To evaluate circulating levels of Galectin-3 in ALL patients, plasma samples from peripheral blood and BM were collected from ALL patients, as well as controls. Interestingly, we found that plasma levels of Galectin-3 in BM from ALL patients were significantly higher than healthy controls (Po0.05) (Figure 1b) as detected by enzyme-linked immunosorbent assay. To further investigate circumstances under which Galectin-3 levels are increased, we used human patient-derived pre-B ALL cells that were passaged in NSG mice and grown ex vivo in the presence of OP9 stromal feeder cells. In this system, the ALL cells adhere to the stromal cells, migrate underneath them and return into the medium in a dynamic fashion. Notably, cells that were harvested from underneath the OP9 layer, and had thus been in direct contact with OP9 cells, expressed a high amount of Galectin-3, while cells in suspension or cells cultured without OP9 for 24 h had low expression of cell surface or intracellular Galectin-3 as measured Accepted article preview online 13 June 2013; advance online publication, 5 July 2013
